OC014—Clinical Usefulness Of Therapeutic Concentration Monitoring For Imatinib Dosage Individualization: Results From The Randomized Controlled I-Come Trial

e6 Volume 35 Number 8S those obtained by DPS or GC-MS levels, suggesting that a fraction of Bu binds to blood cells. Conclusion: This novel method can be applied with only 5 μ L of whole blood for routine therapeutic drug monitoring of Bu with accuracy and faster turnaround times in HSCT. Possibility of using capillary blood for dried blood sampling is under evaluation for its feasibility and accuracy to monitor Bu levels in pediatric patients. Disclosure of Interest: None declared.